LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Architectures of Schizophrenia Compared in Different Populations

By LabMedica International staff writers
Posted on 05 Dec 2019
Print article
Image: Colored positron emission tomography (PET) scans of axial sections through a healthy brain (upper) and a schizophrenic brain (lower). Genetic architectures of schizophrenia in East Asian and European populations have been compared (Photo courtesy of WebMD)
Image: Colored positron emission tomography (PET) scans of axial sections through a healthy brain (upper) and a schizophrenic brain (lower). Genetic architectures of schizophrenia in East Asian and European populations have been compared (Photo courtesy of WebMD)
While the common genetic variants contributing to schizophrenia in East Asian individuals appear to broadly resemble those found in Europeans, polygenic risk scores (PRS) for the condition cannot necessarily be transferred from one population to the next.

Although many common variants and loci have been implicated in schizophrenia, most past studies have focused on individuals of European ancestry. That suggests far more variants are left to be identified but also makes it difficult to know how well the known associations between schizophrenia and variants hold up in other populations.

A team of scientists collaborating with those at Massachusetts General Hospital (Boston, MA, USA) performed a genome-wide association study focused on 22,778 East Asian individuals with schizophrenia and 35,362 without, shoring up findings from the first 13,305 cases and 16,244 controls with additional validation and meta-analysis. Their analyses led to 19 loci with 21 genome-wide significant ties to schizophrenia in East Asians, including 14 associations not identified in a prior schizophrenia study in individuals with Chinese ancestry.

The investigators noted that the risk loci included many parts of the genome where allele frequencies differ in East Asian and European populations, although analyses that incorporated linkage disequilibrium and common variant clues suggested that the genetic architecture of schizophrenia risk is comparable for parts of the genome outside of the immune-related major histocompatibility complex region. The team also saw similar selection signatures, overrepresented gene sets, and other similarities when they compared the East Asian genetic data with results from prior schizophrenia studies in Europeans.

With a meta-analysis on East Asian and European individuals, including 56,418 cases and more than 78,800 controls, the team highlighted 208 schizophrenia associations at 123 known and 53 new loci, narrowing in on apparent causal variants at 44 loci with additional fine-mapping analyses. Even so, PRSs for schizophrenia that were developed in Europeans performed more poorly in the East Asian individuals and vice versa, reduced predictive abilities that the authors suspected might stem from allele frequency, linkage disequilibrium, and other population-related differences.

The authors concluded that their study highlights the importance of including all major ancestral groups in genomic studies, both as a strategy to improve the power to find disease associations and to ensure that the findings have maximum relevance for all populations. The study was published on November 18, 2019 in the journal Nature Genetics.

Related Links:
Massachusetts General Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Centromere B Assay
Centromere B Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.